clinical trial · NCT06613880
Standard Immunosuppressive Therapy Combined With Romiplostim N01 as First-line Treatment for Severe Aplastic Anemia
Institute of Hematology & Blood Diseases Hospital, China·phase2·recruiting·n = 48
Aplastic AnemiaTPO Receptor Agonistsstandard IST combined with Romiplostim N01
brief summary
This prospective, single center, single-arm study aims to evaluate the efficacy and safety of anti-human T lymphocyte porcine immunoglobulin (p-ALG) in combination with cyclosporine and Romiplostim in treating severe aplastic anemia (SAA). It will include 48 patients with newly diagnosed SAA.
started
Oct 24, 2024
primary completion
Jan 31, 2026
completion
Sep 30, 2026
last updated
Dec 4, 2024
official title
A Prospective, Single Center, Single-arm Study on the Efficacy and Safety of Standard Immunosuppressive Therapy Combined With Romiplostim N01 as First-line Treatment for Severe Aplastic Anemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol